Protagonist Therapeutics announced the nomination of PN-881 as a development candidate, a potential best-in-class oral peptide IL-17 antagonist. This candidate is being developed for immune-mediated skin diseases, targeting three IL-17 dimers (AA, AF, FF).
The nomination of PN-881 highlights the versatility and continued innovation of Protagonist's proprietary peptide engineering technology platform. This oral peptide is designed to offer biologics-like high potency and a broad spectrum of activity.
IND-enabling studies for PN-881 are currently underway, with the company anticipating the initiation of a Phase 1 study in the fourth quarter of 2025. This advancement expands Protagonist's pipeline into a new therapeutic area with significant market potential.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.